Nucleic acid scavengers inhibit thrombosis without increasing bleeding

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 32, 2012, Pages 12938-12943

  Jain, Shashank ^a   Pitoc, George A ^a   Holl, Eda K ^a   Zhang, Ying ^b   Borst, Luke ^c   Leong, Kam W ^b   Lee, Jaewoo ^a   Sullenger, Bruce A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Duke University   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Hemorrhage; Platelet; Polyphosphates DNA RNA

Indexed keywords

ANTICOAGULANT AGENT; PAMAM G3; POLYAMINE DERIVATIVE; POLYMER; POLYPHOSPHATE; SCAVENGER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CAROTID ARTERY INJURY; CONTROLLED STUDY; DNA BINDING; IN VITRO STUDY; IN VIVO STUDY; LUNG EMBOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA BINDING; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; CALORIMETRY; CAROTID ARTERY INJURIES; FIBRINOLYTIC AGENTS; MICE; NUCLEIC ACIDS; POLYPHOSPHATES; PULMONARY EMBOLISM; THROMBELASTOGRAPHY; THROMBOSIS;

ANIMALIA; MUS;

EID: 84864709265     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1204928109     Document Type: Article

References (29)

1. Moscucci M (2002) Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: Rationale for new antithrombotic agents. J Invasive Cardiol 14:55B-64B.
2. Mannucci PM, Franchini M (2011) Old and new anticoagulant drugs: A minireview. Ann Med 43:116-123.
3. Spyropoulos AC (2008) Brave new world: The current and future use of novel anticoagulants. Thromb Res 123(Suppl 1):S29-S35.
4. Roger VL, et al. (2011) Heart disease and stroke statistics, 2011 update: A report from the American Heart Association. Circulation 123:e18-e209.
5. Fanikos J, et al. (2007) Adverse drug events in hospitalized cardiac patients. Am J Cardiol 100:1465-1469. (Pubitemid 47576029)
6. Moore TJ, Cohen MR, Furberg CD (2007) Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 167:1752-1759. (Pubitemid 47403063)
7. Haas S (2009) New anticoagulants: Towards the development of an "ideal" anticoagulant. Cor Vasa 38:13-29.
8. Kannemeier C, et al. (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 104:6388-6393. (Pubitemid 47186104)
9. Nakazawa F, et al. (2005) Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J 385:831-838. (Pubitemid 40208845)
10. Fuchs TA, et al. (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107:15880-15885.
11. Choi SH, Smith SA, Morrissey JH (2011) Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 118:6963-6970.
12. Smith SA, Morrissey JH (2008) Polyphosphate enhances fibrin clot structure. Blood 112:2810-2816.
13. Mutch NJ, Engel R, Uitte DW, Philippou H, Ariens RA (2010) Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 115:3980-3988.
14. Muller F, et al. (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139:1143-1156.
15. Oney S, et al. (2009) Development of universal antidotes to control aptamer activity. Nat Med 15:1224-1228.
16. Lee J, et al. (2011) Nucleic acid-binding polymers as anti-inflammatory agents. Proc Natl Acad Sci USA 108:14055-14060.
17. Esfand R, Tomalia DA (2001) Poly(amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications. Drug Discov Today 6:427-436. (Pubitemid 32328297)
18. Svenson S, Tomalia DA (2005) Dendrimers in biomedical applications: Reflections on the field. Adv Drug Deliv Rev 57:2106-2129. (Pubitemid 41759389)
19. Smith SA, et al. (2010) Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 116:4353-4359.
20. Malik N, et al. (2000) Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 65:133-148. (Pubitemid 30122922)
21. Harrington RA, et al. (2008) Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:670S-707S. (Pubitemid 351892975)
22. Wiviott SD, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015. (Pubitemid 350106708)
23. Stone GW, et al. (2007) Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: One-year results from the ACUITY trial. JAMA 298:2497-2506. (Pubitemid 350223536)
24. Levi M, Eerenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9:1705-1712.
25. Wang X, Xu L (2005) An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res 115:95-100. (Pubitemid 39572761)
26. Hirsh J, et al. (2008) Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:141S-159S. (Pubitemid 351892966)
27. Gailani D, Lasky NM, Broze GJ, Jr (1997) A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 8:134-144. (Pubitemid 27211727)
28. Pauer HU, et al. (2004) Targeted deletion of murine coagulation factor XII gene: A model for contact phase activation in vivo. Thromb Haemost 92:503-508.
29. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D (1999) Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 93:1825-1830. (Pubitemid 29128482)